Is tremelimumab on the market?

Tremelimumab was first approved by the U.S. Food and Drug Administration (FDA) in October 2022 and can be used in combination with durvalumab (durvalumab) to treat hepatocellular carcinoma (uHCC), It is also being studied in other cancers, such as colon cancer, pancreatic cancer, non-small cell lung cancer (NSCLC) and malignant melanoma. After receiving recommendations from the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use in December 2022, temselimumab was approved for use in combination with durvalumab.

Temtumumab attacks tumors by stimulating the immune system in the body. CytotoxicT lymphocytes (CTL) can recognize and destroy cancer cells. There is also an inhibitory mechanism (immune checkpoint) to interrupt this destruction. Texitumumabturns off this inhibitory mechanism and allowsCTLs to continue destroying cancer cells. Texitumumab can bindCTLA-4 protein, which is expressed on the surface of activated T lymphocytes and inhibits the killing of cancer cells. Temtumumab blocks the binding of the antigen-presenting cell ligands B7.1 and B7.2 to CTLA-4, thereby inhibiting the downregulation of B7-CTLA-4-mediated T cell activation. B7.1 or B7.2 may interact with another T cell surface receptor protein, CD28, resulting in B7-CD28-mediated T cell activation independent of B7-CTLA-4-mediated inhibition.

Tesetumumab is an emerging cancer immunotherapy drug that has not yet been launched in China, so it has not been included in the medical insurance. Domestic patients cannot yet purchase this drug. The U.S. version of temsitumumab’s original drug has been on the market overseas for a short time, and the price is not yet clear. There is currently no known generic version of temsitumumab that has been produced and launched. For specific prices and drug details, please consult Yaode’s medical consultant.